Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

This study has been withdrawn prior to recruitment.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00404937

Purpose

The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation

Condition	Intervention	Phase
Post-Surgical Inflammation	Drug: Tobradex (Antibiotic steroid combination)	Phase III

Drug Information available for: Tobramycin Tobramycin sulfate

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	700
Study Start Date:	December 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404937

Locations

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Terry Wiernas

Alcon Research

More Information

Study ID Numbers:	C-05-60
Study First Received:	November 28, 2006
Last Updated:	September 10, 2007
ClinicalTrials.gov Identifier:	NCT00404937
Health Authority:	France: Institutional Ethical Committee

Study placed in the following topic categories:

Tobramycin
Inflammation

Additional relevant MeSH terms:

Pathologic Processes

ClinicalTrials.gov processed this record on January 14, 2009